

INTERNATIONAL
STANDARD

ISO
3826

First edition
1993-03-01

**Plastics collapsible containers for human
blood and blood components**

Poches en plastique souple pour le sang et les produits du sang

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993



Reference number
ISO 3826:1993(E)

Contents

Page

1	Scope	1
2	Normative references	1
3	Dimensions and designation	2
4	Design	3
5	Requirements	4
6	Packaging	7
7	Marking and labelling	7
8	Application of tests	8
9	Anticoagulant and/or preservative solution	8

Annexes

A	Chemical tests	9
B	Physical tests	14
C	Biological tests	15

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993

© ISO 1993

All rights reserved. No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from the publisher.

International Organization for Standardization
Case Postale 56 • CH-1211 Genève 20 • Switzerland

Printed in Switzerland

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

International Standard ISO 3826 was prepared by Technical Committee ISO/TC 76, *Transfusion, infusion and injection equipment for medical use*.

Annexes A and B form an integral part of this International Standard. Annex C is for information only.

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993

Introduction

In some countries national pharmacopoeia or other government regulations are legally binding and these requirements may take precedence over this International Standard.

The manufacturers of the plastics container or the suppliers are expected to disclose in confidence to the national control authority, if requested by them, full details of the plastics material(s) and the components of the materials and their methods of manufacture, details of manufacture of the plastics containers including the chemical names and quantities of any additives, whether incorporated by the manufacturer of the containers or present in the raw material, as well as full details of any additives that have been used.

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993

Plastics collapsible containers for human blood and blood components

1 Scope

1.1 This International Standard specifies requirements, including performance requirements for di-(2-ethylhexyl)phthalate (DEHP) plasticized poly(vinyl chloride) (PVC) for plastics collapsible, non-vented, sterile containers complete with collecting tube outlet port(s), integral needle and with optional transfer tube(s), for the collection, storage, processing, transport, separation and administration of blood and blood components. The containers may contain anticoagulant and/or preservative solutions, depending on the application envisaged. These requirements are intended to

- a) ensure that the quality of blood and blood components is maintained as high as possible;
- b) make possible efficient and safe collection, identification, storage, separation and transfusion of the contents, with special attention to reducing to a minimum the risks resulting from
 - contamination, in particular microbiological contamination,
 - air embolism,
 - errors in identification of containers and any representative samples of contents,
 - interaction between the container and its contents;
- c) ensure functional compatibility when used in combination with transfusion sets as specified in ISO 1135-4;

d) provide maximum resistance to breakage and deterioration in a package of minimal mass and volume.

1.2 The requirements specified in this International Standard also apply to multiple units of plastics containers, e.g. to double, triple or quadruple units.

1.3 The term “plastics containers” is used throughout this International Standard to mean the container complete with collecting tube and needle, port(s), anticoagulant and/or preservative solutions and transfer tube(s) and associated container(s), where applicable.

1.4 Unless otherwise specified, all tests specified in this International Standard apply to the plastics container as prepared ready for use.

2 Normative references

The following standards contain provisions which, through reference in this text, constitute provisions of this International Standard. At the time of publication, the editions indicated were valid. All standards are subject to revision, and parties to agreements based on this international Standard are encouraged to investigate the possibility of applying the most recent editions of the standards indicated below. Members of IEC and ISO maintain registers of currently valid International Standards.

ISO 247:1990, *Rubber — Determination of ash.*

ISO 1135-3:1986, *Transfusion equipment for medical use — Part 3: Blood-taking set.*

ISO 1135-4:1987, *Transfusion equipment for medical use — Part 4: Transfusion sets for single use.*

3 Dimensions and designation

3.1 Dimensions

See figure 1 and table 1. Only the dimensional values shown in figure 1 are binding; the dimensions given in table 1 are for guidance purposes only.

NOTES

1 The figure illustrates the components of a plastics container and, apart from the dimensions shown, does not form part of the requirements of this International Standard.

2 For guidance, additional dimensions are given in table 1. These dimensions are optional and are not requirements of this International Standard.




Figure 1 — Schematic representation of plastics container

Table 1 — Dimensions for plastics containers, label areas and nominal capacity (for guidance purposes only)

Dimensions in millimetres

Nominal capacity ml	Inside width b_1	Inside height h_1	Size of label area	
			$b_2 \pm 5$	$h_2 \pm 5$
100	75	120	60	85
250	120	130	90	85
400	120	170	100	100
500	120	185	100	100

3.2 Designation example

Designation example of a plastics collapsible container with a nominal capacity of 500 ml complying with the requirements specified in this International Standard:

Plastics container ISO 3826 - 500

4 Design

4.1 General

The design of the plastics container shall provide for the safe and convenient collection, storage, processing, transport, separation and administration of whole blood and blood components. The design and manufacture shall not adversely affect the preservation of blood and blood components. The container shall permit the preparation of plasma or centrifuged or resuspended cellular components with a minimal hazard of contamination by microorganisms. The container shall be functionally compatible with the transfusion set specified in ISO 1135-4. Its design shall also ensure that it can be used in a centrifuge cup.

4.2 Air content

4.2.1 The total volume of air contained in the blood collection pathway and the container used for the collection of blood and for each transfer container and its associated tubing shall not exceed 10 ml. The volume of air contained in each additional transfer container and associated tubing shall not exceed 10 ml.

4.2.2 When used in accordance with the manufacturer's instructions, the plastics container shall be capable of being filled with blood without air being introduced.

4.3 Emptying under pressure

The plastics container filled with a volume of water at a temperature of $23\text{ °C} \pm 2\text{ °C}$ equal to its nominal capacity and connected to a transfusion set as specified in ISO 1135-4 inserted in an outlet port (see 4.8) shall empty without leakage within 2 min when gradually squeezed between two plates to an internal pressure of 40 kPa above atmospheric pressure.

4.4 Pilot samples

The plastics container shall be designed so that pilot samples of unmistakable identity can be collected for the performance of appropriate laboratory tests without the closed system of the container being penetrated.

4.5 Rate of collection

4.5.1 The plastics container shall be flexible enough to offer minimum resistance to filling under normal conditions of use.

4.5.2 The plastics container shall be designed so that it is capable of being filled to its nominal capacity in less than 8 min when tested in accordance with B.2.

4.6 Collecting and transfer tube(s)

4.6.1 The plastics container may be provided with one or more collecting or transfer tube(s) to allow the collection and separation of blood and blood components.

The transfer tube shall be fitted with a device, which acts first as a seal and, when broken, permits the free flow of blood components in either direction.

4.6.2 The tubes shall be such that they can be sealed hermetically and do not collapse under normal use.

4.6.3 The plastics container, filled with water (see note 4 under 5.2.8) to its nominal capacity and sealed, and the tubes connected to the plastics container, shall form a hermetic seal and a tight leakproof joint which will withstand, without leakage occurring, a tensile force of 20 N, applied to the tubing for 15 s. The tensile force shall be applied at right angles to the edge of the joint and in the longitudinal axis of the plane of the container at a temperature of $23\text{ °C} \pm 2\text{ °C}$.

There shall be no leakage at the junctions and the container shall also conform to the requirements specified in 5.2.8.

4.6.4 Under visual inspection, the tubing shall not display any cracks, blisters, kinks or other defects.

4.7 Blood-taking needle

The needle shall be integral with the collecting tube and covered by a protective cap. The protective cap shall prevent leakage of anticoagulant and/or preservative solution from the plastics container during storage, shall maintain the sterility of the fluid path and shall be readily removable. The protective cap shall be tamper-evident and manufactured so that either it is impossible to replace or any attempt at manipulating it is blatantly obvious.

The blood-taking needle, as specified in ISO 1135-3, shall withstand, without working loose from the assembly, a tensile force of 20 N applied along the longitudinal axis of the tubing for 15 s.

4.8 Outlet port(s)

4.8.1 The plastics container shall be provided with one or more outlet ports for the administration of blood and blood components through a transfusion set. The port(s), which shall have a puncturable, non-resealable closure, shall allow connection of a transfusion set without leakage on insertion or during conditions of use, including emptying under pressure (see 4.3). To ensure functional interchangeability, the port(s) shall be of such size and design to allow insertion of a transfusion set having a closure-piercing device in accordance with ISO 1135-4. Before the closure is pierced by the point of the closure-piercing device, the outlet port(s) shall be tightly occluded by the closure-piercing device.

4.8.2 Each outlet port shall be fitted with a hermetically sealed, tamper-evident protector to maintain the sterility of the internal surface.

4.9 Suspension

The plastics container shall have adequate means of suspension or positioning, which do not interfere with use of the container during collection, storage, processing, transport and administration. The means of suspension or positioning shall be capable of with-

standing a tensile force of 20 N applied along the longitudinal axis of the outlet port(s) for 60 min at a temperature of $23\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$ without breaking.

5 Requirements

5.1 General

The plastics container shall be transparent, virtually colourless (see 5.3.2), flexible, sterile, non-pyrogenic, free from toxicity (see 5.4) and non-frangible under conditions of use (see 5.2.5). It shall be compatible with the contents under normal conditions of storage. The container shall be sterilized in the final stage of manufacture, and the container shall not be tacky or become tacky during sterilization or, subsequently, during storage for its shelf-life at temperatures not exceeding $40\text{ }^{\circ}\text{C}$.

The plastics container shall be stable biologically, chemically and physically with respect to its contents during its shelf-life and shall not permit penetration of microorganisms. Any substances leached from the container by the anticoagulant and/or preservative solution, blood and blood components by either chemical interaction or physical dissolution, shall be within the limits specified.

In many countries there are national pharmacopoeias, government regulations or standards detailing suitable tests for assessing such chemical or physical interactions. However, if no such regulations are provided, the test methods indicated in table 2 shall be used.

5.2 Physical requirements

5.2.1 Conditions of manufacture

All processes involved in the manufacture, assembly and storage of the plastics container shall be carried out under clean and hygienic conditions in compliance with the appropriate national authorities in accordance with the relevant legislation and international agreements. Every practicable precaution shall be taken at all stages to reduce the risk of adventitious contamination by microorganisms or foreign matter.

5.2.2 Sterilization

5.2.2.1 The plastics container shall have been sterilized by autoclaving or any other method approved by the national control authority.

5.2.2.2 The method of sterilization used shall not adversely affect the materials or contents nor cause any loosening of joints and deterioration of welds in the plastics material nor any major alteration in the shape of the plastics container.

5.2.2.3 The manufacturer shall be able to produce evidence acceptable to the national control authority of the effectiveness of the sterilization process actually used. If required by the national control authority, positive controls to check the effectiveness of sterilization shall be included in each sterilization lot.

5.2.3 Transparency

When tested with the suspension as specified in B.1, the opalescence of the suspension shall be perceptible when viewed through the plastics container as compared with a similar container filled with water.

5.2.4 Coloration

The material of the plastics container shall not be coloured to such an extent that assessment of the colour of the blood is adversely affected.

5.2.5 Thermal stability

The plastics container, filled to half of its nominal capacity with purified water, shall withstand storage at $-80\text{ }^{\circ}\text{C}$ for 24 h, subsequent immersion in water at $50\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$ for 20 min, and returning to room temperature. The plastics container shall meet the requirements of 4.6.3, 4.9, 5.2.7 and 5.2.8.

NOTE 3 If a refrigerant solution is used, the plastics container may be enclosed in a protective bag to avoid direct contact between the refrigerant solution and the plastics container.

5.2.6 Vapour transmission

The plastics container, without an over-package, shall be filled with the labelled volume of anticoagulant and/or preservative solution, if any, and with a volume of sodium chloride solution [$\rho(\text{NaCl}) = 9\text{ g/l}$] equal to the nominal capacity, sealed and labelled ready for use. The plastics container shall then be capable of being stored in still air conditions for six weeks at a temperature of $5\text{ }^{\circ}\text{C} \pm 1\text{ }^{\circ}\text{C}$ and a maximum relative humidity of 55 % without loss of more than 2 % (m/m) of water from the solution.

5.2.7 Resistance to distortion

When centrifuged, the plastics container filled with water to its nominal capacity shall withstand an acceleration of 5 000g for 30 min at temperatures of $4\text{ }^{\circ}\text{C}$ and $37\text{ }^{\circ}\text{C}$ without becoming permanently distorted.

5.2.8 Resistance to leakage¹⁾

When filled to nominal capacity with purified water and sealed, the plastics container shall not develop leaks under conditions of centrifugation at 5 000g for 30 min at $4\text{ }^{\circ}\text{C}$ followed by 30 min at $37\text{ }^{\circ}\text{C}$. In addition, the container, similarly filled to nominal capacity and sealed, shall show no leakage on being gradually squeezed between two plates, lined with indicator paper, to an internal pressure equivalent to 100 kPa above atmospheric pressure at $23\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$, reached within 1 min and maintained for 10 min.

NOTE 4 When the plastics container is filled with anti-coagulant solution, such as an ACD solution or other solutions with similar pH, leakage may be detected by pressing the container against sheets of blue litmus paper and observing the development of pink spots on the paper. For solutions of other pH, the same method with an appropriate indicator may be used. Alternative methods affording at least the same degree of sensitivity may be used.

5.2.9 Permanence of marking and labelling

Any attempt to peel the label off shall result in the label being destroyed.

When tested in accordance with B.3, the label(s) shall not separate from the containers after removal from water. Printing on the label or on the container shall remain legible.

5.3 Chemical requirements

5.3.1 Requirements for extract

The limits specified in table 2 shall not be exceeded when the appropriate tests are carried out on the extract obtained in accordance with A.2 and A.3.9.

5.3.2 Requirements for plastics material

When plastics materials are tested by the methods given in column 3 of table 3, the limits shown in column 2 of the table shall not be exceeded.

1) The test using centrifugation specified in 5.2.8 can be carried out in a single operation with the test specified in 5.2.7.

Table 2 — Chemical limits on extracts

Characteristics	Limit	Test method in
Oxidizable matter	≤ 2 ml of $c(0,5 \text{ Na}_2\text{S}_2\text{O}_3) = 0,01 \text{ mol/l}$	A.3.1
Ammonia (NH₃)	$\leq 2 \text{ mg/l}$	A.3.2
Chloride ions (Cl⁻)	$\leq 4 \text{ mg/l}$	A.3.3
Acidity or alkalinity	$\leq 0,4 \text{ ml of } c(\text{NaOH}) = 0,01 \text{ mol/l}$, or $\leq 0,8 \text{ ml of } c(\text{HCl}) = 0,01 \text{ mol/l}$	A.3.4
Residue on evaporation	$\leq 3 \text{ mg/100 ml}$	A.3.5
Opalescence	Slightly opalescent, but not more pronounced than that of reference suspension 2	A.3.6
Coloration	No coloration	A.3.7
Ultraviolet (UV) absorption	Extinction $\leq 0,2$ in the range of 230 nm to 360 nm	A.3.8
Extractable di(2-ethylhexyl) phthalate (DEHP)	$\leq 10 \text{ mg/100 ml}$	A.3.9

Table 3 — Chemical limits on plastics material

Characteristics	Limit	Test method in	
Ash	$\leq 1 \text{ mg/g}$	A.4.1	
Elements	Ba, Pb	$\leq 1 \text{ mg/kg}$	A.4.2.1
	Cd, Sn	$\leq 0,6 \text{ mg/kg}$	A.4.2.2
Vinyl chloride monomer	$\leq 1 \text{ } \mu\text{g/g}$	A.4.3	

5.4 Biological requirements

The plastics container shall not release any substances which may adversely affect the therapeutic effectiveness of blood and blood components, including those substances which may exhibit toxic, cytotoxic, bacteriostatic, bactericidal, pyrogenic or haemolytic reactions.

In many countries there are national pharmacopoeias, government regulations or standards detailing suitable tests for assessing biological safety and sterility. However, if no such regulations are provided, the test method specified in table C.1 should be used.

5.4.1 Requirements for type test

The type test shall be established and assessed by an expert(s) in the transfusion field and on toxicology of plastics material. It shall cover the elements in 5.4.1.1 to 5.4.1.4.

5.4.1.1 General biological safety of plastics container

Materials shall be assessed for biocompatibility by carrying out suitable tests for those properties detailed in table C.1 and the results of the tests shall indicate freedom from toxicity.

5.4.1.2 Compatibility of plastics container with process of manufacture and sterilization

The process of manufacture and sterilization and the prolonged contact with the anticoagulant solution, blood and blood components shall not alter properties of the plastics material and of the plastics container itself.

5.4.1.3 Compatibility of material of plastics container with anticoagulant and/or preservative solution, blood and blood components

Migration after sterilization and prolonged contact of the constituents or additives of the plastics material shall not alter the properties of the anticoagulant and/or preservative solution, of blood and blood components or cause any toxicological risk for the patient.

5.4.1.4 Biological safety of plastics container with cellular elements of blood and blood components

The type test shall cover this aspect.

5.4.2 Requirements for lot test

5.4.2.1 Sterility

The plastics container and its contents shall be supplied sterile; guidance on testing for sterility is given in C.3.1.

5.4.2.2 Pyrogens

The plastics container supplied shall be assessed for freedom from pyrogens using a suitable test (guidance on testing for pyrogens is given in C.3.2) and the result shall indicate that the plastics container is pyrogen-free.

6 Packaging

The plastics container shall be placed inside a sealed over-package to meet the requirements specified below.

6.1 The plastics container shall not lose more than 2,5 % (*m/m*) of water from the anticoagulant and/or preservative solution during storage for 1 year at 55 % humidity, 23 °C ± 2 °C and atmospheric pressure.

6.2 The shelf-life of a plastics container shall be established by the manufacturer on the basis of stability data. When containing anticoagulant and/or preservative solution, the shelf-life shall not be greater than the time during which the water loss equals 5 % (*m/m*), but in any case shall not be less than 2 years.

NOTE 5 For the purposes of this International Standard, the term "shelf-life" refers to the period between the date of sterilization and the date after which the plastics containers should not be used for the collection of blood.

6.3 The interior surface of the over-package should not interact with any of its contents and shall be treated to prevent growth of mould or fungus inside the package. If chemical fungicides are used, evidence shall be provided to show there has been no harmful penetration of, or deleterious effect on, the plastics container and its contents.

6.4 The over-package shall be sealed in such a manner as to be tamper-evident and to prevent opening or reclosing without displaying signs that the seal has been destroyed.

6.5 The over-package shall be strong enough to resist damage under conditions of normal handling and use.

6.6 The over-package shall be adequately pest-proof, account being taken of the hazards of the region in which it is to be used.

6.7 The plastics container and components shall be arranged in the over-package in a manner which will prevent the collecting tube and connecting tube(s) [transfer tube(s)] from kinking and acquiring a permanent set.

7 Marking and labelling

Marking and labelling of a plastics container shall conform to applicable national regulations and shall include the requirements specified in 7.1 to 7.4.

7.1 Marking on plastics container

The label shall contain the following information:

- a) description of the contents;
- b) nature and volume, in millilitres, or mass, in grams, of anticoagulant and/or preservative solution and any other material introduced, and the volume, in millilitres, or mass, in grams, of blood and blood components to be collected;
- c) statement: "STERILE AND PYROGEN-FREE";
- d) instruction: "DO NOT USE IF THERE IS ANY VISIBLE SIGN OF DETERIORATION", or precise alternative wording;
- e) instruction: "CONTAINER NOT TO BE RE-USED", or precise alternative wording;
- f) instruction: "DO NOT VENT";
- g) instructions for use of the plastics container, including conditions of storage of the plastics container when filled with blood and blood components;
- h) manufacturer's name and address and/or the name and address of the supplier responsible;
- i) lot designation;
- j) expiry date for the unused plastics container indicated by the instruction: "DO NOT FILL WITH BLOOD AFTER ...".

7.2 Marking on over-package

The label shall contain the following information:

- a) manufacturer's name and address and/or the name and address of the supplier responsible;
- b) description of the contents;
- c) expiry date;
- d) instruction: "NOT TO BE USED MORE THAN n^2 DAYS AFTER REMOVAL FROM THE OVER-PACKAGE";
- e) lot designation.

7.3 Marking on transit container

The label shall contain the following information:

- a) manufacturer's name and address and/or the name and address of the supplier responsible;
- b) description of the contents;
- c) storage conditions.

7.4 Label requirements

The label shall be such that

- a) identification of the blood, i.e. ABO and Rh group, and reference number can be recorded on the plastics container, and an appropriate reference number recorded on the pilot tubes; there shall also be adequate space for other entries required by national regulations;
- b) by leaving a portion of the plastics container visible and free of markings, the contents can be adequately inspected visually;
- c) there is no diffusion of ink from the label into the plastics material of the container which is harmful to the contents;
- d) the printing on the label remains legible at the time of use;
- e) a pen or pencil can be used for writing on the label;

- f) any adhesive used on the label does not permit or support growth of microorganisms and has no deleterious effect on the plastics container or its contents.

The label attached to the container by the manufacturer should not, prior to filling, make reference to any special information concerning the blood or blood components or the nature of the blood or blood components to be collected.

8 Application of tests

NOTE 6 For guidance purposes only, typical type and lot tests are given in 8.1 and 8.2.

8.1 Type test

On new plastics formulation(s), on already agreed formulation(s) in which any change has been made or on changing of the anticoagulant and/or preservative solution, the full range of chemical tests specified in A.3 and A.4, a series of suitable biological safety tests (guidance on biological testing is given in annex C) and the tests in annex B may be repeated.

8.2 Lot test

On each manufacturing lot of finished plastics containers, tests for the requirements specified in 4.2, 4.3, 4.6.3, 4.7 to 4.9, 5.2.4, 5.2.7 to 5.2.9 and in clauses 7 and 9 shall be carried out. In addition the tests for sterility and freedom from pyrogens (see 5.4.2.1 and 5.4.2.2) shall be carried out on each sterilization lot.

NOTES

7 For plastics containers containing anticoagulant and/or preservative solution, the term "lot" means that quantity of plastics containers prepared, filled from a single batch of anticoagulant solution and sterilized within a continuous working period.

8 For plastics containers not containing anticoagulant and/or preservative solution, the term "lot" means that quantity of plastics containers prepared within one working day and sterilized in one cycle.

9 Anticoagulant and/or preservative solution

The quality of the anticoagulant and/or preservative solution, if any, shall satisfy the requirements of the national pharmacopoeia and national regulations.

2) n is determined by the manufacturer.

Annex A (normative)

Chemical tests

A.1 General

Take materials for testing from the blood and blood derivatives contact materials of the finished, empty and sterilized plastics containers, i.e. in the state in which they would be used transfusion, collection, separation and administration procedures, including the plastics sheet used for the collecting bag and the plastics tubings used for the collecting tube, transfer tube and any parts that will come into contact with blood and blood components.

A.2 Preparation of extract and blank

A.2.1 Sample preparation

The tests specified in A.3 require a surface area of 1 250 cm² of each plastics sample in sheet or tubing form.

A.2.1.1 Sample in sheet form

Use a sample free from printing or label, having a surface area of 625 cm² (total surface area of both sides: 1 250 cm²). Cut the samples into pieces of approximately 10 cm² area (one side).

A.2.1.2 Sample in tubing form

Calculate the length required l , in centimetres, as follows:

$$l = \frac{1\,250}{3,14 (d_1 + d_2)}$$

where

d_1 is the inner diameter, in centimetres;

d_2 is the outer diameter, in centimetres.

Cut the tubing into sections approximately 5 cm in length.

A.2.2 Preparation of extract

To remove any surface contaminants, particulate matter, lint, anticoagulant and/or preservative solution, etc., place the cut sample in a stoppered glass container with 100 ml of cold distilled water, shake

several times and drain off the water. Repeat this operation once.

Place the cut sample in a container of borosilicate glass with 250 ml of distilled water and cover the opening of the container. Heat the container in saturated steam at $121\text{ }^\circ\text{C} \pm 1\text{ }^\circ\text{C}$ for 20 min, quickly cool to room temperature ($23\text{ }^\circ\text{C} \pm 5\text{ }^\circ\text{C}$) and adjust the volume to 250 ml with distilled water. It is of no significance if the plastics sample tends to stick together slightly.

A.2.3 Preparation of blank

For use as a control make a blank preparation in a corresponding manner, omitting the plastics sample.

A.3 Tests on extract

A.3.1 Oxidizable matter

Add 20 ml of potassium permanganate solution [$c(\text{KMnO}_4) = 0,002\text{ mol/l}$] and 1 ml of sulfuric acid solution [$c(\text{H}_2\text{SO}_4) = 1\text{ mol/l}$] to 20 ml of the extract (see A.2.2) in a conical (Erlenmeyer) flask of borosilicate glass. Keep the mixture at room temperature ($23\text{ }^\circ\text{C} \pm 5\text{ }^\circ\text{C}$) for 15 min. Add 0,1 g of potassium iodide and 5 drops of starch solution. Titrate with sodium thiosulfate solution [$c(0,5\text{ Na}_2\text{S}_2\text{O}_3) = 0,01\text{ mol/l}$].

At the same time carry out a blank titration.

Determine the difference in the volumes of sodium thiosulfate solution consumed in the two titrations.

A.3.2 Ammonia

The extract shall comply with a suitable limit test for ammonia.

A.3.3 Chloride ions

Add 0,3 ml of silver nitrate solution [$c(\text{AgNO}_3) = 0,1\text{ mol/l}$] to 0,15 ml of diluted nitric acid. Add the resultant solution to 15 ml of the extract.

Prepare a reference solution in the same way using 12 ml of chloride standard solution (5 ppm of Cl^-) and 3 ml of water.

Shake the mixtures. After 2 min, the extract shall not be more turbid than the reference solution. Direct daylight shall be avoided.

A.3.4 Acidity or alkalinity

On addition of 2 drops of phenolphthalein solution to 10 ml of the extract, the solution shall not be coloured red. On addition of 0,4 ml of sodium hydroxide solution [$c(\text{NaOH}) = 0,01 \text{ mol/l}$], the solution shall be coloured red.

On addition of 0,8 ml of hydrochloric acid [$c(\text{HCl}) = 0,01 \text{ mol/l}$], the red colour shall disappear. Addition of 5 drops of methyl red solution shall produce an orange colour.

A.3.5 Residue on evaporation

Evaporate 100 ml of the extract to dryness on a water-bath and dry at 105 °C to constant mass.

Determine the mass of the residue.

A.3.6 Clarity and degree of opalescence

Using identical test tubes of colourless, transparent, neutral glass with a flat base and an internal diameter of 15 mm to 25 mm, compare the liquid to be examined with a reference suspension freshly prepared as described below, the depth of the layer being 40 mm. Compare the solutions in diffused daylight 5 min after preparation of the reference suspension, viewing them vertically against a black background. The diffusion of light shall be such that reference suspension 1 can readily be distinguished from water and that reference suspension 2 can readily be distinguished from reference suspension 1.

A.3.6.1 Reagents

A.3.6.1.1 Hydrazine sulfate solution

Dissolve 1 g of hydrazine sulfate in water and dilute to 100 ml. Allow to stand for 4 h to 6 h.

A.3.6.1.2 Hexamethylenetetramine solution

Dissolve 2,5 g of hexamethylenetetramine in 25 ml of water in a 100 ml glass-stoppered flask.

A.3.6.1.3 Primary opalescent suspension

Add to the solution of hexamethylenetetramine (A.3.6.1.2) 25 ml of the hydrazine sulfate solution (A.3.6.1.1). Mix and allow to stand for 24 h.

This suspension is stable for 2 months, provided that it is stored in a glass container free from surface defects. The suspension shall not adhere to the glass and shall be well mixed before use.

A.3.6.1.4 Standard of opalescence

Dilute 15 ml of the primary opalescent suspension (A.3.6.1.3) to 1 000 ml with water.

This suspension shall be freshly prepared and may be stored for at most 24 h.

A.3.6.1.5 Reference suspensions

Prepare the reference suspensions in accordance with table A.1. Mix and shake before use.

Table A.1 — Reference suspensions

Reference suspension	Volumes in millilitres			
	1	2	3	4
Standard of opalescence	5	10	30	50
Water	95	90	70	50

A.3.6.2 Expression of results

A.3.6.2.1 A liquid is deemed to be clear if its clarity is the same as that of water or of the solvent used, when examined under the conditions described above, or if its opalescence is not more pronounced than that of reference suspension 1.

A.3.6.2.2 A liquid is deemed to be slightly opalescent if its opalescence is more pronounced than A.3.6.2.1, but not more pronounced than that of reference suspension 2.

A.3.6.2.3 A liquid is deemed to be opalescent if its opalescence is more pronounced than A.3.6.2.2, but not more pronounced than that of reference suspension 3.

A.3.6.2.4 A liquid is highly opalescent if its opalescence is more pronounced than A.3.6.2.3, but not more pronounced than that of reference suspension 4.

A.3.7 Degree of coloration

The examination of the degree of coloration of liquids in the range brown-yellow-red is carried out by one of the two methods specified in A.3.7.1 and A.3.7.2.

A.3.7.1 Method 1

Using matched tubes of colourless, transparent, neutral glass having an internal diameter of 12 mm, compare 2 ml of the liquid to be examined with 2 ml of water. Compare the colours in diffused daylight viewing them horizontally against a white background.

A.3.7.2 Method 2

Using matched tubes of colourless, transparent, neutral glass having an internal diameter of 16 mm, compare 10 ml of the liquid to be examined with 10 ml of water. Examine the column of liquid down the vertical axis of the tube in diffused daylight against a white background.

A.3.7.3 Expression of results

A liquid is deemed to be colourless if it has the appearance of water when examined under the conditions as specified for method 1 or 2.

A.3.8 Ultraviolet (UV) absorption

Determine the UV absorption of the extract in a 1 cm cell against the blank. The absorbance is determined in the range from 230 nm to 360 nm.

A.3.9 Determination of extractable di-(2-ethylhexyl)phthalate (DEHP)**A.3.9.1 Reagents**

A.3.9.1.1 Ethanol: from 95,1 % (V/V) to 96,6 % (V/V), ρ from 0,805 0 g/ml to 0,812 3 g/ml.

A.3.9.1.2 Extraction solvent: ethanol water mixture having a density of 0,937 3 g/ml to 0,937 8 g/ml; determined with a pycnometer.

A.3.9.1.3 Di-(2-ethylhexyl)phthalate ($C_{24}H_{38}O_4$): a colourless, oily liquid insoluble in water, soluble in organic solvents: ρ from 0,982 g/ml to 0,986 g/ml, refractive index at 20 °C n_D^{20} 1,486 to 1,487.

A.3.9.2 Preparation of standard solutions**A.3.9.2.1 Solution 1**

Dissolve 1 g of DEHP (A.3.9.1.3) in ethanol (A.3.9.1.1) and dilute to 100 ml with ethanol.

A.3.9.2.2 Solution 2

Dilute 10 ml of solution (A.3.9.2.1) to 100 ml with ethanol.

A.3.9.2.3 Standard solutions A to E

A: Dilute 20 ml of solution 2 (A.3.9.2.2) to 100 ml with extraction solvent (A.3.9.1.2) (DEHP content: 20 mg/100 ml).

B: Dilute 10 ml of solution 2 to 100 ml with extraction solvent (DEHP content: 10 mg/100 ml).

C: Dilute 5 ml of solution 2 to 100 ml with extraction solvent (DEHP content: 5 mg/100 ml).

D: Dilute 2 ml of solution 2 to 100 ml with extraction solvent (DEHP content: 2 mg/100 ml).

E: Dilute 1 ml of solution 2 to 100 ml with extraction solvent (DEHP content: 1 mg/100 ml).

A.3.9.3 Calibration curves

Measure the maximum absorbance of the standard solutions (A.3.9.2.3) at 272 nm, using the extraction solvent as the reference solution and plot a curve of absorbance against DEHP concentrations.

A.3.9.4 Extraction procedure

Fill the empty plastics container to half of the nominal capacity through the collecting tube with a volume of extraction solvent heated to 37 °C. Expel the air completely from the container and seal the collecting tube. Immerse the filled container in a horizontal position in a water-bath maintained at 37 °C \pm 1 °C for 60 min \pm 1 min without shaking. Remove the container from the water-bath, invert it gently ten times and transfer the contents to a glass flask.

Measure the maximum absorbance at 272 nm using the extraction solvent as the reference solution.

A.3.9.5 Expression of results

Determine the quantity of extractable DEHP by comparing the result obtained for the plastics container (see A.3.9.4) with the calibration curve of absorbance for the standard solutions (see A.3.9.3).

A.4 Tests on plastics material**A.4.1 Determination of ash**

Use a sample in sheet form or in tubing form, free from printing or label.

The residue of ash shall be determined in accordance with ISO 247:1990, method B.

A.4.2 Determination of elements**A.4.2.1 Determination of barium and lead content**

Ignite 10 g of the plastics material in a silica crucible. Dissolve the residue in 5 ml of hydrochloric acid ($\rho = 1,18$ g/ml) and evaporate to dryness on a water-bath. Dissolve the residue in 10 ml of hydrochloric acid solution [$c(\text{HCl}) = 1$ mol/l].

Determine the barium and lead content by atomic absorption spectroscopy (AAS).

A.4.2.2 Determination of tin and cadmium content

Place 5 g of the plastics material in a combustion flask. Add 30 ml of sulfuric acid ($\rho = 1,83$ g/ml) and heat until a black syrupy mass is obtained. Add a 30 % (V/V) solution of hydrogen peroxide until a colourless liquid is obtained. Reduce the volume to 5 ml. Cool and dilute to 50 ml with water.

Determine the tin content by flameless atomic absorption spectroscopy and the cadmium content by flame atomic absorption spectroscopy (AAS).

A.4.3 Determination of vinyl chloride monomer

A.4.3.1 Reagents

During the analysis, unless otherwise stated, use only reagents of recognized analytical grade.

WARNING — Vinyl chloride is a hazardous substance and is a gas at ambient temperatures.

Vinyl chloride is a carcinogen.

Vinyl chloride should be handled in a well-ventilated fume cupboard and operators should wear gloves made of material, such as neoprene, which does not readily absorb vinyl chloride. Care should be taken in the safe disposal of any solution containing vinyl chloride.

A.4.3.1.1 Purified diethyl ether reagent: Diethyl ether [(C₂H₅)₂O], purified for use as the internal standard.

A.4.3.1.2 Dimethylacetamide: (*N, N*-Dimethylacetamide (C₄H₉NO), $M_r = 87,12$; a colourless liquid, miscible with water and with many organic solvents, $\rho = 0,94$ g/ml, boiling point ≈ 165 °C.

A.4.3.1.3 Vinyl chloride, purity higher than 99,5 %.

A.4.3.1.4 Dimethylstearylamide³⁾: *N, N*-Dimethylstearylamide (C₂₀H₄₁NO₂), $M_r = 327,5$; a white or off-white mass, soluble in many organic solvents, melting point ≈ 51 °C.

A.4.3.1.5 Polyethyleneglycol 400³⁾, $M_r \approx 400$; a colourless or almost colourless, viscous liquid, miscible with water, highly soluble in acetone, alcohol and chloroform.

3) Hallcomid M18 (dimethylstearylamide) and Carbowax 400 (polyethyleneglycol 400) are examples of suitable products available commercially. This information is given for the convenience of users of this International Standard and does not constitute an endorsement by ISO of these products.

A.4.3.2 Preparation of internal standard solutions

Using a microsyringe, inject 10 μ l of diethyl ether (A.4.3.1.1), as the internal standard, into 20 ml of dimethylacetamide (A.4.3.1.2), immersing the tip of the needle in the solvent. Immediately before use dilute the solution to 1 000 times its volume with dimethylacetamide (A.4.3.1.2).

A.4.3.3 Preparation of test solution

Place 1 g of the material to be examined in a 50 ml vial and add 10 ml of the internal standard solution (A.4.3.2). Close the vial and secure the stopper. Shake. Place the vial in a water-bath at 60 °C ± 1 °C for 2 h.

A.4.3.4 Preparation of vinyl chloride primary solution

Place 50 ml of dimethylacetamide (A.4.3.1.2) in a 50 ml vial, close the vial and secure the stopper. Weigh the vial and its contents to the nearest 0,1 mg. Fill a 50 ml gas syringe with gaseous vinyl chloride (A.4.3.1.3). Fit a hypodermic needle to the syringe and inject the volume of vinyl chloride slowly into the vial shaking gently and avoiding contact between the liquid and the needle. Reweigh the vial. The increase in mass is about 60 mg.

1 μ l of the solution thus obtained contains about 1,2 μ g of vinyl chloride.

A.4.3.5 Preparation of vinyl chloride standard solution

Dilute 5 ml of the vinyl chloride primary solution to 20 ml with dimethylacetamide (A.4.3.1.2).

A.4.3.6 Preparation of reference solutions

Place 10 ml of the internal standard solution (A.4.3.2) in each of six 50 ml vials. Close the vials and secure the stoppers. Inject 1 μ l, 2 μ l, 3 μ l, 5 μ l and 10 μ l of the vinyl chloride standard solution (A.4.3.5), respectively, into five of the vials. The six solutions thus obtained contain 0 μ g, $\approx 0,3$ μ g, $\approx 0,6$ μ g, $\approx 0,9$ μ g, $\approx 1,5$ μ g and $\approx 2,5$ μ g of vinyl chloride. Shake. Place the vials in a water-bath at 60 °C ± 1 °C for 2 h.

A.4.3.7 Chromatographic procedure

Carry out the chromatographic procedure by using

- a **stainless steel column**, 3 m long and with an external diameter of 3 mm, packed with silanized diatomaceous earth for gas chromatography

impregnated with 5 % (m/m) of dimethylstearylamine (A.4.3.1.4) and 5 % (m/m) of polyethyleneglycol 400 (A.4.3.1.5);

b) **nitrogen for chromatography** as carrier gas at a flow rate of 30 ml/min;

c) **a flame-ionization detector.**

Maintain the temperature of the column at 45 °C, that of the injection port at 100 °C and that of the detector at 150 °C.

Inject 1 ml of the gas phase aspirated from the headspace over the test solution (A.4.3.3) and from the headspace over the reference solutions (A.4.3.6) into the column.

Determine the amount of vinyl chloride in the test solution.

A.4.3.8 Expression of results

Calculate the amount of vinyl chloride, expressed as micrograms per gram of test material.

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993

Annex B (normative)

Physical tests

B.1 Transparency test

Fill the empty plastics container equal to its nominal capacity with a volume of the primary opalescent suspension (A.3.6.1.3) diluted to an absorbance of 0,37 to 0,43 at 640 nm (dilution factor about 1:16) in a 1 cm cell.

B.2 Test for rate of collection

From a reservoir containing 500 ml of a fluid at $37\text{ °C} \pm 2\text{ °C}$ having a viscosity of $3,4 \times 10^{-6}\text{ m}^2/\text{s}$ at 37 °C and under pressure of 9,3 kPa, allow the container to fill at a temperature of $23\text{ °C} \pm 2\text{ °C}$ through a blood-taking needle with an internal diameter of 1,4 mm in the same hydrostatic plane as the top of

the bag. The blood-taking needle shall comply with ISO 1135-3.

NOTE 9 A suitable liquid for use in this test is a solution of glucose in water (400 g/l).

B.3 Test for permanence of labelling

The plastics container, filled to capacity and sealed, shall be stored for 5 days at a temperature of $5\text{ °C} \pm 1\text{ °C}$. This initial period shall be followed by a period of 24 h at a maximum temperature of -40 °C , then 24 h at $5\text{ °C} \pm 1\text{ °C}$. The labelled and/or printed plastics container shall then be submerged in tap water maintained at a temperature of $20\text{ °C} \pm 1\text{ °C}$ for 24 h.

STANDARDSISO.COM : Click to view the full PDF of ISO 3826:1993

Annex C (informative)

Biological tests

C.1 General

The biological safety of materials used for plastics containers depends to a large degree on the particular nature of the end-use application. It is not possible to specify a set of biocompatibility test methods which will be necessary and sufficient to establish biological safety for all materials and applications. The area of biological safety testing of materials is a relatively new field with improved methods evolving rapidly; therefore, by necessity, this annex only gives guidelines.

C.2 Type tests

The biological test methods listed in table C.1 should be considered as minimum requirements. Additional tests may be performed if the current state of the art requires such tests.

The test methods shall be carried out in accordance with requirements as specified in national pharmacopoeias, other government introduction regulations or national standards.

Where national regulations do not exist, these tests may be carried out in accordance with the recommended regulations as listed in table C.1 and shall be assessed by an expert on toxicology of plastics material.

C.3 Lot test

C.3.1 Sterility

It shall be carried out in accordance with the requirements of national pharmacopoeias or national standards detailing suitable sterility tests. However, where no such regulations exist, the test method recommended under C.2.7 in table C.1 should be used.

C.3.2 Pyrogens

It shall be carried out in accordance with the requirements of national pharmacopoeias or national standards detailing suitable sterility tests. However, where no such regulations exist, the test method recommended under C.2.6 in table C.1 should be used.

C.4 Haemolysis

It is desirable to specify an internationally comparable haemolysis test in this International Standard because a test for haemolytic effect is not included in most pharmacopoeias and/or standards.

C.4.1 Preparation of erythrocyte suspension

Dilute one volume of freshly prepared human blood, anticoagulated in accordance with the national pharmacopoeia, with five volumes of a sterile solution of sodium chloride [$\rho(\text{NaCl}) = 9 \text{ g/l}$]. Centrifuge for 5 min at 1 500g to 2 000g in a swing-out centrifuge. Remove the supernatant layer and repeat the treatment of the erythrocytes under the same conditions with the same volume of sodium chloride solution.

Dilute the erythrocytes thus obtained with a sterile solution of sodium chloride [$\rho(\text{NaCl}) = 9 \text{ g/l}$] in the proportion of 1:9. This suspension shall be used within 6 h after its preparation when kept at room temperature.

C.4.2 Procedure

Evaporate 125 ml of the extract (A.2.2) at a temperature of 100 °C. Dissolve the residue in 5 ml of a sterile solution of sodium chloride [$\rho(\text{NaCl}) = 9 \text{ g/l}$]. Add 1 ml of the erythrocyte suspension (C.4.1) and suspend the mixture for 20 min at 37 °C \pm 1 °C. Centrifuge the mixture for 5 min at 1 500g to 2 000g in a swing-out centrifuge.

Prepare the blank suspension at the same time under the same conditions, without however adding the dried residue on evaporation of the extract.

NOTE 10 The test described may not detect volatile constituents of the extract; however, it is expected that by concentration of the extract a higher sensitivity is obtained.

Measure the absorbance of the supernatant layer at 540 nm in a 1 cm cell, using the blank suspension as a reference. The absorbance of the test solution should not differ by more than 10 % from the blank sample.